Defining infection risk of bispecific antibodies for myeloma ow.ly/uNS450TuATg #InsideBloodAdvances #IBAs #lymphoidneoplasia

Proposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myeloma ow.ly/I0IP50TuAug #clinialtrialsandobservations #lymphoidneoplasia #plasmacelldisorders

Patients with MM patients have increased CD16/CD226Low NK cell subsets characterized by adhesion defects and reduced effector functions. ow.ly/ZF6T50Tr8n9 #immunobiologyandimmunotherapy #clinicaltrialsandobservations #lymphoidneoplasia #multiplemyeloma

SHERLOCK has the potential to improve access to life-saving therapies for clinically actionable fusion-driven leukemias. ow.ly/kryl50Tr7ZH #myeloidneoplasia #lymphoidneoplasia

Homoharringtonine inhibits the NOTCH/MYC pathway and exhibits antitumor effects in T-cell acute lymphoblastic leukemia ow.ly/oImb50Tr7qC #lymphoidneoplasia

The oral farnesyltransferase inhibitor, tipifarnib, as a single agent, produces responses in 40% of patients with heavily pretreated PTCL. ow.ly/WfhA50TktgV #clinicaltrialsandobservations #lymphoidneoplasia

The epigenetic spectrum of IgM gammopathies ow.ly/sl7u50Tr7Ca #lymphoidneoplasia

Global DNA methylation analysis reveals significant DMRs comparing WM with IgM-MGUS and IgM gammopathies with controls across genomic regions. ow.ly/R1Hq50Tr89T #lymphoidneoplasia

Frailty was associated with higher adjusted health care utilization and costs in all phases except end-of-life where there was no difference. ow.ly/huzx50TkuEq #healthservicesandoutcomes #lymphoidneoplasia

Ibrutinib and venetoclax in combination for chronic lymphocytic leukemia: synergy in practice ow.ly/1qb050TpbX2 #chroniclymphocyticleukemia #lymphoidneoplasia

T-cell lymphoblastic lymphoma compared with T-cell acute lymphoblastic leukemia: similar subtypes and different fusions ow.ly/hI6n50TpbNS #lymphoidneoplasia #lymphoma

ATM kinase rheostA-T impacts cancer outcomes ow.ly/PxZH50TmrXI #lymphoidneoplasia

The presence of CLL cells delays T-cell receptor–mediated CAR T-cell activation and impairs proliferation and restimulation. ow.ly/XXby50Tktp3 #immunobiologyandimmunotherapy #lymphoidneoplasia

Acalabrutinib plus venetoclax and rituximab resulted in high clinical and molecular response rates in patients with TN MCL. ow.ly/nc3550TksTM #clinicaltrialsandobservations #lymphoidneoplasia

Transformation of marginal zone lymphoma to Hodgkin lymphoma ow.ly/5lkM50Tkr5t #lymphoidneoplasia

The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas ow.ly/CXRr50TkrZB #drugadvances #clinicaltrialsandobservations #immunobiologyandimmunotherapy #lymphoidneoplasia

Proliferation-promoting pathways are suppressed after the first cycle of treatment with pirtobrutinib in BTK-WT and -mutated CLL. ow.ly/cicy50TkuuR #lymphoidneoplasia #clinicaltrialsandobservations

The germ line ATM pathogenic variant functional class is a robust outcome predictor, which can be applied to therapy stratification. ow.ly/lulC50Tms2x #lymphoidneoplasia #clinicaltrialsandobservations

BTK C481S was most common in both groups; in the acalabrutinib arm, low-VAF T474I (9/47; 8 co-occurring with C481S) but no L528W was seen. ow.ly/R6eF50TgBGs #clinicaltrialsandobservations #lymphoidneoplasia

MCL BR-based induction and R-based maintenance gave 88% overall response rate, 91% measurable residual disease–negative and median PFS 6.9 years. ow.ly/3eA850TgB1C #lymphoidneoplasia #clinicaltrialsandobservations